Sichuan Kelun Pharmaceutical Co.Ltd(002422) independent director
Independent opinions on matters related to the 10th meeting of the 7th board of directors
As an independent director of Sichuan Kelun Pharmaceutical Co.Ltd(002422) (hereinafter referred to as “the company”), in accordance with relevant laws and regulations such as the rules for independent directors of listed companies, the guidelines for self discipline supervision of listed companies of Shenzhen Stock Exchange No. 1 – standardized operation of listed companies on the main board, the guidelines for corporate governance of listed companies and the articles of association, the working system of independent directors and other relevant provisions, On the basis of careful review of relevant materials and based on the position of independent judgment, we express our independent opinions on the relevant matters considered at the 10th meeting of the seventh board of directors as follows: I. independent opinions on the proposal on further clarifying the company’s public issuance of convertible corporate bonds
The company’s plan to publicly issue convertible corporate bonds was reviewed and approved at the 44th meeting of the sixth board of directors and the 2020 annual general meeting of shareholders. The issuance scheme of convertible corporate bonds issued by the company this time complies with the requirements of laws, regulations and normative documents such as the company law of the people’s Republic of China, the securities law of the people’s Republic of China and the like. The scheme is practical and feasible, which is conducive to improving the company’s core competitiveness and sustainable profitability, and in line with the company’s long-term development objectives and the interests of all shareholders, There is no situation that damages the interests of minority shareholders. We agree to the matters related to the issuance plan of this public offering of convertible bonds.
2、 Independent opinions on the proposal on public issuance of convertible corporate bonds for listing
The company will handle matters related to the listing of convertible corporate bonds on Shenzhen Stock Exchange after the issuance of convertible corporate bonds. The matter does not harm the interests of minority shareholders. Therefore, we agree to the matters related to the listing of convertible corporate bonds in this public offering.
3、 Independent opinions on the proposal on opening a special account for raising funds through public issuance of convertible corporate bonds and signing a supervision agreement for raising funds
The opening of a special account for the raised funds of the company’s public offering of convertible corporate bonds and the signing of the raised funds supervision agreement comply with the guidelines for the supervision of listed companies No. 2 – supervision requirements for the management and use of raised funds of listed companies (revised 2022), the guidelines for the self discipline supervision of listed companies of Shenzhen Stock Exchange No. 1 – standardized operation of listed companies on the main board, and The management system for the use of raised funds and other relevant provisions can standardize the company’s management, storage and use of raised funds and effectively protect the legitimate rights and interests of investors. We agree to open a special account for the raised funds of this public offering of convertible corporate bonds and sign a supervision agreement for the raised funds.
(there is no text on this page, which is the signature page of Sichuan Kelun Pharmaceutical Co.Ltd(002422) independent directors’ independent opinions on matters related to the 10th meeting of the seventh board of directors.)
Sichuan Kelun Pharmaceutical Co.Ltd(002422)
Independent director: (signature)
Ren Shichi
Chen Jie
Gao Jinbo
specific date
